Twist Bioscience Co. (NASDAQ:TWST) CEO Sells $24,892.14 in Stock

Twist Bioscience Co. (NASDAQ:TWST) CEO Emily M. Leproust sold 546 shares of the firm’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $45.59, for a total value of $24,892.14. Following the completion of the transaction, the chief executive officer now owns 672,518 shares in the company, valued at approximately $30,660,095.62. This represents a 0.08 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Twist Bioscience Stock Down 6.0 %

Shares of TWST opened at $45.62 on Wednesday. Twist Bioscience Co. has a 12-month low of $27.41 and a 12-month high of $60.90. The business has a 50-day simple moving average of $46.22 and a two-hundred day simple moving average of $46.48. The stock has a market cap of $2.71 billion, a PE ratio of -12.67 and a beta of 1.85.

Hedge Funds Weigh In On Twist Bioscience

Institutional investors and hedge funds have recently bought and sold shares of the company. Wilmington Savings Fund Society FSB acquired a new position in Twist Bioscience in the 3rd quarter worth about $34,000. Signaturefd LLC grew its position in shares of Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after buying an additional 306 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new stake in shares of Twist Bioscience in the 2nd quarter valued at about $61,000. Beaird Harris Wealth Management LLC bought a new stake in shares of Twist Bioscience in the 3rd quarter valued at about $95,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in shares of Twist Bioscience by 21.9% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company’s stock valued at $98,000 after buying an additional 381 shares during the last quarter.

Analyst Ratings Changes

TWST has been the topic of a number of recent analyst reports. TD Cowen restated a “buy” rating and set a $58.00 target price on shares of Twist Bioscience in a report on Tuesday, November 26th. Evercore ISI raised their target price on Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Wolfe Research assumed coverage on Twist Bioscience in a research report on Friday, December 13th. They set an “outperform” rating and a $60.00 price target on the stock. Robert W. Baird raised their price target on Twist Bioscience from $46.00 to $48.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 19th. Finally, Leerink Partners raised their price target on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $51.90.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.